[Homocysteine as a cardiovascular marker and risk factor].
In context of cardiovascular secondary prevention the D.A.C.H.-Liga (union of scientists from Germany, Austria, and Switzerland doing research on the topic homocysteine) demands that the homocysteine level should be measured and recommends a substitution of folic acid above a value of 10 micromol/l. Numerous studies have proven the therapy's positive effect. Although a threshold could not be acquired in any study there seems to be an association between the homocysteine level and an increased cardiovascular risk. Homocysteine is not only a marker, but also a reason of cardiovascular mortality and morbidity. Further detailed statements concerning homocysteine therapy can be made after completing of current research.
Pietrzik
K
K
Rheinische Friedrich-Wilhelms-Universität Bonn, Institut für Ernährungswissenschaften, Endenicher Allee 11-13, 53115 Bonn, Germany.
D002423:Cause of Death; D005492:Folic Acid / Q000008:administration & dosage; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D020138:Hyperhomocysteinemia / Q000097:blood / Q000150:complications / Q000401:mortality; D009203:Myocardial Infarction / Q000097:blood / Q000401:mortality / Q000517:prevention & control*; D012307:Risk Factors; D055502:Secondary Prevention; D016896:Treatment Outcome; D014805:Vitamin B 12 / Q000008:administration & dosage; D025101:Vitamin B 6 / Q000008:administration & dosage
D006710:Homocysteine; D025101:Vitamin B 6; D005492:Folic Acid; D014805:Vitamin B 12